Repligen (NASDAQ:RGEN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Repligen (NASDAQ:RGEN - Get Free Report) had its price target lifted by investment analysts at JPMorgan Chase & Co. from $190.00 to $200.00 in a report issued on Friday,Benzinga reports. The firm presently has an "overweight" rating on the biotechnology company's stock. JPMorgan Chase & Co.'s target price would indicate a potential upside of 23.86% from the stock's previous close.

Several other equities research analysts also recently weighed in on RGEN. HC Wainwright reissued a "buy" rating and issued a $180.00 price objective on shares of Repligen in a report on Friday. StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research note on Friday, January 3rd. TD Cowen started coverage on shares of Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 price objective on the stock. Canaccord Genuity Group increased their target price on shares of Repligen from $165.00 to $170.00 and gave the stock a "hold" rating in a research note on Friday. Finally, Wolfe Research began coverage on Repligen in a research report on Thursday, November 14th. They issued a "peer perform" rating on the stock. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Repligen presently has an average rating of "Moderate Buy" and an average target price of $181.00.

Remove Ads

Repligen Stock Down 2.0 %

Shares of Repligen stock traded down $3.27 during trading hours on Friday, hitting $161.47. The company had a trading volume of 801,294 shares, compared to its average volume of 624,058. The company's 50-day moving average is $155.30 and its two-hundred day moving average is $148.57. Repligen has a twelve month low of $113.50 and a twelve month high of $203.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The company has a market cap of $9.05 billion, a P/E ratio of -316.61, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Analysts anticipate that Repligen will post 1.72 earnings per share for the current fiscal year.

Institutional Trading of Repligen

Several hedge funds have recently modified their holdings of the business. UMB Bank n.a. raised its position in Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 110 shares in the last quarter. First Turn Management LLC acquired a new position in shares of Repligen during the 3rd quarter worth $13,202,000. Thrivent Financial for Lutherans increased its holdings in shares of Repligen by 6.1% in the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company's stock valued at $95,037,000 after purchasing an additional 36,773 shares in the last quarter. Geneva Capital Management LLC lifted its stake in shares of Repligen by 8.5% in the third quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company's stock valued at $20,638,000 after purchasing an additional 10,908 shares during the period. Finally, TimesSquare Capital Management LLC boosted its holdings in Repligen by 14.6% during the third quarter. TimesSquare Capital Management LLC now owns 275,627 shares of the biotechnology company's stock worth $41,019,000 after buying an additional 35,115 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.